Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin as Add-on Therapy in Type 2 Diabetes
NCT06326034Phase 4Completed
- Start
- May 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dapagliflozin in type 2 diabetes mellitus (T2DM). Primary endpoint: Quality of Life Assessment at 16 weeks. Started May 2022; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06326034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06326034.